Background: Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. Previous observational studies have reported inconsistent findings on this issue. We investigated the association between aspirin use and risk for lung cancer by conducting a meta-analysis.
introduction
Lung cancer is the leading cause of cancer deaths worldwide. Although smoking is a well-established etiological factor for lung cancer [1] , other causes remain unclear. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have received increasing attention owing to their potential as chemopreventive agents against cancer. It has been proposed that aspirin influences cancer risk primarily through its effect on cyclooxygenase (COX) activity [2] [3] [4] [5] [6] [7] [8] [9] . In experimental animal models, aspirin and other NSAIDs have been reported to suppress tumor growth [2, 3] . Observational epidemiological investigations and meta-analyses suggested that regular aspirin use is associated with a reduced risk for cancers of the esophagus [4] , stomach [5, 6] , colon [7, 8] , prostate [9] , and breast [10] .
Several observational studies have examined the relationship between aspirin and other NSAIDs use and lung cancer, with inconsistent results. According to a meta-analysis of 14 observational studies between 1998 and 2003, the odds ratio (OR) was 0.73 [95% confidence interval (CI) 0.63-0.86] for aspirin use and 0.79 (95% CI 0.66-0.95) for NSAID use [11] . In a quantitative review concerning aspirin use and lung cancer risk in 2006, a pooled relative risk (RR) was 0.70 (95% CI 0.56-0.88) for two case-control studies and 0.96 (95% CI 0.91-1.02) for six cohort studies [12] . Recently, two large randomized trials with post-trial follow-up for >20 years have reported no association between regular aspirin use and lung cancer risk [13] .
The purpose of the current study was to investigate the association between aspirin use and lung cancer risk by conducting a meta-analysis of observational studies such as case-control studies and cohort studies by type of study design, quality of study methodology, aspirin dose, duration of aspirin use, smoking status, and histology of lung cancer. case-control studies and cohort studies; these searches were carried out by one of the authors (S-WO) and then confirmed by another author (S-KM).
We also scanned the bibliographies of relevant articles to identify additional studies. As the key words for the literature search, we selected 'aspirin', 'nonsteroidal anti-inflammatory drugs', and 'NSAIDs' for the exposure factors, and 'lung cancer' and 'pulmonary neoplasm' for the outcome factors.
eligibility criteria
We included case-control studies and cohort studies reporting an association between aspirin use and lung cancer risk using ORs or RRs. The current study included only articles written in English. We excluded those studies with no available data for outcome measures, having the same population as other studies (in this case, the first published or more comprehensive study was included in the analysis), having data on mortality only, and reporting standardized incidence ratios (SIRs).
data extraction
All studies retrieved from databases and bibliographies were independently evaluated by two authors of this article (S-WO and S-KM). Disagreements between the evaluators concerning the selected studies were resolved by consensus or in consultation with the third author (JYP). Of the articles found in the three databases, duplicate articles and those that did not meet the selection criteria were excluded. We extracted the following data from the remaining studies: study name (first author, year of publication), journal name, country and design, years enrolled, characteristics and study population age range, exposure assessment, definition of aspirin use, OR or RR with 95% CI, and adjustments. Data abstraction was also carried out by two evaluators, as was study selection.
The methodological quality of the included studies was assessed using the 9-star Newcastle-Ottawa scale for quality of nonrandomized studies in meta-analyses [14] . We considered a high-quality study as one awarded star more than the average stars of the included studies with the same study design since there are no established standard criteria to date. The mean value for the 15 studies assessed was 6.4 stars.
statistical analysis
Adjusted data (adjusted OR or RR with 95% CI) were used for the metaanalysis whenever possible. For the exposure factor, we chose the highest and lowest levels of aspirin use among the various categories in each study (Table 1) . We also carried out subgroup analyses by quality of study methodology, gender, study design type (case-control studies versus cohort studies; for the selection of cases and controls, we classified a nested casecontrol study into a cohort study in the current study), aspirin dose [low dose (£100 mg) or high dose (>100 mg)], duration of aspirin use [short term (<5 years) or long term ( ‡5 years)], smoking status (current, former, or never smokers), and histology of lung cancer (adenocarcinoma, squamous cell carcinoma, or small-cell carcinoma).
The test of heterogeneity in results across studies was carried out using Higgins I 2 , which measures the percentage of total variation across the studies. I 2 is calculated as follows:
where Q is the Cochran's heterogeneity statistic and df the degrees of freedom. Negative values of I 2 are set at zero so that I 2 exists between 0%
(no observed heterogeneity) and 100% (maximal heterogeneity) [30] . An I 2 value >50% was considered to show substantial heterogeneity. We estimated a pooled OR or RR with a 95% CI on the basis of both fixedeffects and random-effects models. When substantial heterogeneity was not found (i.e. if I 2 £50%), the pooled estimate based on the fixed-effects model was represented. When substantial heterogeneity was found (i.e. if I 2 >50%), the pooled estimate based on the random-effects model was represented. The Woolf's method (inverse variance method) was used for a fixedeffects analysis [31] and the DerSimonian-Laird's method for a randomeffects analysis [32] . We used Begg's funnel plot and Egger's test to identify publication bias. If the funnel plot was asymmetrical or the P value was <0.05 by Egger's test, then we assessed that there was publication bias. We used the Stata SE version 10.0 software package (StataCorp, College Station, TX) for the statistical analysis.
results

literature search
In total, 15 studies (6 case-control studies and 9 prospective cohort studies) published between 1989 and 2009 were included in the final analysis. Figure 1 shows a flow diagram, identifying the relevant studies. We identified 1244 articles from the three databases and the bibliographies of relevant articles. After the exclusion of duplicates (n = 139), all remaining articles screened (n = 1105) were reviewed according to their titles and abstracts. Of the 1105 articles, we excluded 1079 articles that did not meet the selection criteria. After reviewing the full text for the remaining 26 articles, we included 15 articles in the final analysis. The main reasons for excluding studies from the final review (n = 11) were as follows: insufficient data (n = 6) [33] [34] [35] [36] [37] [38] , identical cohort (n = 1) [39] , mortality data only (n = 2) [40, 41] , and use of SIRs as an outcome measure (n = 2) [42, 43] . study characteristics Table 1 shows the main characteristics of all the studies included in the final analysis. The study design types were as follows: hospital-based case-control studies (n = 4) [15] [16] [17] [18] , populationbased case-control studies (n = 2) [19, 20] , nested case-control studies (n = 2) [23, 26] , and prospective cohort studies (n = 7) [21, 22, 24, 25, [27] [28] [29] . The countries where the studies had been carried out were as follows: the United States (n = 13) [15-18, 20-25, 27-29] , the UK (n = 1) [26] , and Denmark (n = 1) [19] . The range of enrollment periods for participants across studies was 1971-2007. In the nine cohort studies (nested case-control studies and prospective cohort studies), we identified a total of 9262 cases among 467 831 participants. quality of study methodologies Table 2 shows the quality of study methodology included in the final meta-analysis. The range of quality scores was 4-8; the average score was 6.5. The average scores (standard deviation) of case-control studies and cohort studies were 5.5 (0.57) and 7.1 (0.98), respectively. The high-quality studies (above each study type average) included three of six case-control studies and four of nine cohort studies.
overall use of aspirin and the risk for lung cancer Figure 2 shows the effect of aspirin use on lung cancer risk in a meta-analysis of all studies, including both case-controls studies and prospective cohort studies. In a random-effects meta-analysis of all 15 studies, the overall use of aspirin [21] was excluded from the analysis of cohort studies, the result was not changed (data not shown).
A significant publication bias was found in the selected 15 studies (Begg's funnel plot, asymmetrical; Egger's test, P for bias = 0.006) (Figure 3 ). There was also a significant publication bias in the six case-control studies (Egger's test, P for bias = 0.042), while there was no publication bias in the nine cohort studies (Egger's test, P for bias = 0.082).
subgroup meta-analyses Table 3 shows the effects of aspirin use on lung cancer risk in subgroup meta-analyses by quality of study methodology, gender, aspirin dose, duration of aspirin use, smoking status, and lung cancer histology.
Significant protective effects of aspirin use on lung cancer were observed among the eight low-quality studies (OR, 0.82; 95% CI 0.68-0.99) but not among the seven high-quality studies (OR, 0.90; 95% CI 0.76-1.07) ( Table 3) .
There was no significant association between aspirin use and lung cancer risk regardless of the duration of aspirin use (short term, <5 years; long term, ‡5 years), aspirin dose (low dose, <100 mg; high dose ‡100 mg), smoking status (current, former, or never), or lung cancer histology (adenocarcinoma, squamous cell carcinoma, or small-cell carcinoma).
Aspirin use was associated with a decreased lung cancer risk for men (OR, 0.62; 95% CI 0.48-0.62), while there was no evidence of a preventive effect for women (OR, 0.73; 95% CI 0.50-1.06).
discussion
The findings from this meta-analysis of epidemiological studies, including case-control and cohort studies, indicate that aspirin use was associated with a decreased risk for lung cancer. However, in the subgroup meta-analyses by study design, cohort studies showed no significant decreased risk for lung cancer with aspirin use, while case-control studies showed a significant preventive effect.
These inconsistent findings between two different study designs can be explained by the quality of the study methodologies, included in the current study. Overall, casecontrol studies had a lower mean score than cohort studies, namely, 5.5 and 7.1, respectively. In the subgroup meta-analyses by study quality, significant protective effects of aspirin use on lung cancer were observed only among low-quality studies.
Additionally, most of the included studies in our study used self-administered questionnaires or interviews for the assessment of aspirin use, regarding the item of 'ascertainment of exposure'. Results from observational studies that collected exposure information through questionnaires or retrospective personal interviews without blinding are susceptible to recall bias or selection bias. If the relatively healthy aspirin users were more likely to participate in the study than nonusers, especially If there was no significant difference in the response rate between both groups using a chi-square test (P > 0.05), one point was awarded. as controls, a spurious protective association could be observed. Likewise, the item of 'selection of controls' is related to selection bias in the case-control studies. For example, four of six case-control studies used hospital controls. The use of hospital controls might introduce bias due to the possibility that some controls were suffering from conditions that would make them more likely to use aspirin. Especially, three casecontrol studies classified in the low-quality category did not satisfy the validity for the item of 'adequate definition of lung cancer cases'. These studies used record linkage or self-reports for the case definition, while the other studies reviewed individual pathology reports. Our findings are inconsistent with a previous meta-analysis of observational studies, including case-control studies and cohort studies, regarding the use of NSAIDs and lung cancer. The previous meta-analysis reported that the OR of lung cancer risk was 0.73 (95% CI 0.63-0.86) for aspirin use and 0.79 (95% CI 0.66-0.95) for NSAID use, and that the subgroup metaanalysis of cohort studies also showed a significant positive effect [11] . However, only three cohort studies were included in the subgroup meta-analysis and the analysis of the methodological quality were not reported. Another quantitative review reported the protective effect of aspirin on lung cancer from two case-control studies (OR, 0.70; 95% CI 0.56-0.88), while there was no significant effect from six cohort studies (OR, 0.96; 95% CI 0.91-1.02) [12] . Although these results are consistent with our meta-analysis, there is a limitation that few studies were included. Furthermore, previously mentioned meta-analyses included cohort studies of lung cancer mortality [40, 41] that were excluded from our final analysis. However, when we added mortality data in the analysis of cohort studies with incidence data, its finding was similar to that of only incidence data (RR, 1.00; 95% CI 0.92-1.08).
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When we combined both case-control and cohort studies, we identified a publication bias. From the results of the funnel plot, we could interpret that studies having a null association between aspirin use and lung cancer risk were not included (or published) in our meta-analysis. This publication bias might lead to the overall overestimated positive association between them. However, when we assessed publication bias by type of study, publication bias was observed only in the case-control studies and not in the cohort studies.
Aspirin and other NSAIDs inhibit COX enzymes, which convert arachidonic acid into prostaglandins [44] . The proposed mechanism for aspirin's effect on cancer lies with its inhibition of the COX-2 enzyme, which is induced early in the development of numerous tumors through its effect on apoptosis, cell migration, and angiogenesis [1, 45] . Observational studies and meta-analyses have suggested that regular aspirin use is associated with reduced risk for cancers of the esophagus [3] , stomach [4, 5] , colon [6, 7] , prostate [8] , and breast [9] . However, in contrast with the observational Figure 2 . Association between aspirin use and lung cancer risk by type of study design. The Physicians' Health Study found no effect on colorectal cancer after the administration of aspirin 325 mg every alternate day over a 5-year period [46] . Results from the Women's Health Study (WHS) also reported that alternate-day use of low-dose aspirin (100 mg) for an average 10 years of treatment did not lower risk for total, breast, colorectal, or other site-specific cancer incidences [47] . In the WHS, a marginally statistically significant protective effect on lung cancer was observed (RR, 0.78; 95% CI 0.59-1.03; P = 0.08), which was significant for lung cancer mortality. In contrast, two UK large randomized trials with post-trial follow-up for >20 years reported a significant protective effect of aspirin use on colorectal cancer incidence, using ‡300 mg for 5 years, with a latency of 10 years [13] . However, in this study, there were no significant effects of aspirin use on lung cancer (hazard ratio, 0.96; 95% CI 0.70-1.32). More recently, a long-term follow-up of three large trials of daily low-dose aspirin (75-300 mg) reported that allocation to aspirin reduced the 20-year risk for colon cancer [48] . Even though the results from previously mentioned randomized, controlled trials (RCTs) are suggestive of a reduction in colorectal cancer risk, we have an insufficient amount of RCTs data to draw definite conclusions in noncolorectal cancers, including lung cancer.
In subgroup meta-analyses, a significant protective effect of aspirin use on lung cancer was observed among men but not among women. Some biological evidence has suggested that there is an association between sexual hormones and lung cancer risk. Estrogen receptors are expressed in both normal lung tissue and lung tumors, and these receptors may influence the association between aspirin use and lung cancer [49] [50] [51] [52] . However, these findings should be evaluated further, given the small number of studies.
Our meta-analysis has several limitations. First, definitions of aspirin use in each study were quite heterogeneous. For the exposure definition, we used the highest and lowest levels of aspirin use among the various categories in each study. Dose and duration of aspirin use were various according to the definition of each study. It could lead to heterogeneity across the included studies. Secondly, even though there was no association between duration or dose of aspirin use and the risk for lung cancer in our analysis, more trials are required to conclude their association because of the paucity of data published on this issue. Thirdly, the exclusion of non-English language articles might bias our findings. However, there have been few studies on this topic written in languages other than English. Upon reviewing their English abstracts, none of them met our main eligibility criteria; therefore, this exclusion criterion would not have substantially altered our results. Finally, we should mention common limitations of metaanalysis, i.e. 'pooled results could incorporate the biases of individual studies and embody new sources of bias, mostly because of the selection studies and the inevitable heterogeneity among them' [53] .
In summary, our meta-analysis indicates that there is no association between aspirin use and risk for lung cancer on the basis of the findings of cohort studies, which generally give a higher level of evidence than case-control studies. Although a subgroup meta-analysis of case-control studies showed 
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a preventive effect of aspirin use on lung cancer, interpretation should be cautious because of the potential biases of lowquality case-control studies. The findings from these observational studies need to be confirmed in future research, such as in more prospective cohort studies or RCTs providing the highest level of evidence.
